Leal Therapeutics raises $30m Series A
Eli Lilly, OrbiMed and other investors participated in the financing.
Leal Therapeutics raised $30 million in Series A financing on August 17. Participants included Eli Lilly and Company, OrbiMed, Newpath Partners, Euclidean Capital, Dementia Discovery Fund, Chugai Venture Fund, Alexandria Venture Investments and PhiFund. The company develops neuro-metabolic therapeutics for schizophrenia and ALS.